Maui Imaging

About Maui Imaging

Maui Imaging, a Tucson, Arizona-based company, is focused on advancing medical imaging with its Computed Echo Tomography (CET) platform. Founded in 2006 by the late Don Specht and his son, David Specht, the company emerged from a vision to overcome the limitations of conventional ultrasound. Don Specht's background was a unique blend of medical imaging, AI, and aerospace, including co-founding the first AI company for cancer detection in mammograms (R2 Technology) and working as a senior scientist at Lockheed Martin on space telescopes. This diverse experience led him to apply engineering principles from multiple aperture telescopes to ultrasound technology, aiming to image through physical barriers. David Specht, the current CEO, is a former Air Force flyer turned entrepreneur who has led the company since his father's passing in 2019, steering it towards its mission.

The company's core technology, CET, represents a significant departure from traditional ultrasound. It is designed to visualize anatomy through and around obstacles like bone, gas, and medical implants, which typically obstruct standard ultrasound waves. This is achieved by using a proprietary concave probe that transmits and receives sound energy from multiple angles, processing the reflected data with patented algorithms to construct a complete image. This process generates a large volumetric dataset that can be used for creating multiple image slices and for analysis by AI diagnostic tools. The company holds a substantial intellectual property portfolio, with over 160 granted patents and more pending.

Maui Imaging's flagship product is the K3900 imaging system, which received FDA 510(k) clearance in October 2023. The system, priced around $85,000, is portable and designed to be operated by personnel with minimal training, increasing its accessibility. The primary markets for this technology are trauma care, neurosurgery, and interventional radiology. A key client is the U.S. Department of Defense (DoD), which awarded Maui Imaging a $4 million contract in August 2024 to support trauma medicine for the military, particularly in resource-limited or mass casualty situations. The technology is being tested at major trauma centers, like the University of Maryland Shock Trauma Center, to validate its effectiveness in improving patient outcomes. The business model involves direct sales and leveraging distribution partnerships, such as an exclusive U.S. distribution agreement with Acertara Acoustic Laboratories for hospitals. The company has successfully raised over $40 million, including a $14 million Series D round in July 2025 to scale manufacturing, sales, and marketing efforts.